Research advances in Coronavirus Disease 2019 and rheumatoid arthritis
-
摘要: 类风湿关节炎（RA）是一种慢性炎症性疾病，主要累及滑膜，还可侵蚀骨关节，甚至导致关节功能丧失。新型冠状病毒肺炎（COVID-19）患者可有肌肉骨骼症状，且危重症者病死率高。细胞因子在RA和COVID-19的发病中起重要作用，但其具体机制尚不清楚，研究应用于RA的抗风湿药物或可指导COVID-19的治疗。本文对COVID-19与RA的相关研究进行综述，以期进一步提高对疾病发病机制、临床表现和治疗药物的认识，从而改善患者预后。Abstract: Rheumatoid arthritis(RA) is an autoimmune disease characterized by chronic synovial inflammation,which eventually leads to different degrees of bone and cartilage erosion,even disability of joint.The patients of Coronavirus Disease 2019(COVID-19) can have musculoskeletal symptoms,and the mortality rate of critical patients is high.Cytokines play an important role in the pathogenesis of RA and COVID-19,the exact mechanism of which is unknown,and commonly used drugs of RA may guide the treatment of COVID-19.This article mainly reviewed the correlation between COVID-19 and RA in order to further improve the understanding of thepathogenesis,clinical manifestations,and treatment drugs of the disease and improve patients' outcomes.
-
Keywords:
- Coronavirus Disease 2019 /
- rheumatoid arthritis /
- cytokine storm /
- treatment drugs
-
-
[1] SMOLEN J S,ALETAHA D,BARTON A.Rheumatoid arthritis[J].Nat Rev Dis Primers,2018,4: 18001. doi: 10.1038/nrdp.2018.1
[2] JOO Y B,LIM Y H,KIM K J,et al.Respiratory viral infections and the risk of rheumatoid arthritis[J].Arthritis Res Ther,2019,21(1): 199. doi: 10.1186/s13075-019-1977-9
[3] HOFFMANN M,KLEINE-WEBER H,SCHROEDER S,et al.SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor[J].Cell,2020,181(2): 271-280. doi: 10.1016/j.cell.2020.02.052
[4] ZHAO Y,ZHAO Z,WANG Y,et al.Single-cell RNA expression profiling of ACE2,the receptor of SARS-CoV-2[J].Am J Respir Crit Care Med,2020,202(5): 756-759. doi: 10.1164/rccm.202001-0179LE
[5] TERENZI R,MANETTI M,ROSA I,et al.Angiotensin Ⅱ type 2 receptor (AT2R) as a novel modulator of inflammation in rheumatoid arthritis synovium[J].Sci Rep,2017,7(1): 13293. doi: 10.1038/s41598-017-13746-w
[6] WU Y,LI M,ZENG J,et al.Differential expression of renin-angiotensin system-related components in patients with rheumatoid arthritis and osteoarthritis[J].Am J Med Sci,2020,359(1): 17-26. doi: 10.1016/j.amjms.2019.10.014
[7] HIRANO T,MURAKAMI M.COVID-19: a new virus,but a familiar receptor and cytokine release syndrome[J].Immunity,2020,52(5): 731-733. doi: 10.1016/j.immuni.2020.04.003
[8] 靳云洲,李明芳,郑胜,等.新型冠状病毒肺炎患者不同病情状态下淋巴细胞、白细胞介素-6及炎症指标的变化[J].实用临床医药杂志,2020,24(6): 1-4. [9] LAI Q,SPOLETINI G,BIANCO G,et al.SARS-CoV2 and immunosuppression: a double-edged sword[J].Transpl Infect Dis,2020,22(6): e13404. http://journals.lww.com/anesthesia-analgesia/Fulltext/2020/10000/Human_Leukocyte_Antigen_DR_Deficiency_and.1.aspx
[10] ELEMAM N M,HANNAWI S,MAGHAZACHI A A.Role of chemokines and chemokine receptors in rheumatoid arthritis[J].Immunotargets Ther,2020,9: 43-56. doi: 10.2147/ITT.S243636
[11] MANGALMURTI N,HUNTER C A.Cytokine storms: understanding COVID-19[J].Immunity,2020,53(1): 19-25. doi: 10.1016/j.immuni.2020.06.017
[12] MARKS M,MARKS J L.Viral arthritis[J].Clin Med Lond Engl,2016,16(2): 129-134.
[13] MEMISH Z A,PERLMAN S,VAN KERKHOVE M D,et al.Middle East respiratory syndrome[J].Lancet,2020,395(10229): 1063-1077. doi: 10.1016/S0140-6736(19)33221-0
[14] CIAFFI J,MELICONI R,RUSCITTI P,et al.Rheumatic manifestations of COVID-19: a systematic review and meta-analysis[J].BMC Rheumatol,2020,4: 65. doi: 10.1186/s41927-020-00165-0
[15] HYLDGAARD C,ELLINGSEN T,HILBERG O,et al.Rheumatoid arthritis-associated interstitial lung disease: clinical characteristics and predictors of mortality[J].Respiration,2019,98(5): 455-460. doi: 10.1159/000502551
[16] DAI Y,WANG W,YU Y,et al.Rheumatoid arthritis-associated interstitial lung disease: an overview of epidemiology,pathogenesis and management[J].Clin Rheumatol,2021,40(4): 1211-1220. doi: 10.1007/s10067-020-05320-z
[17] WOOTTON S C,KIM D S,KONDOH Y,et al.Viral infection in acute exacerbation of idiopathic pulmonary fibrosis[J].Am J Respir Crit Care Med,2011,183(12): 1698-1702. doi: 10.1164/rccm.201010-1752OC
[18] FONSECA M,SUMMER R,ROMAN J.Acute exacerbation of interstitial lung disease as a sequela of COVID-19 pneumonia[J].Am J Med Sci,2021,361(1): 126-129. doi: 10.1016/j.amjms.2020.08.017
[19] HUANG H,ZHANG M,CHEN C,et al.Clinical characteristics of COVID-19 in patients with preexisting ILD: a retrospective study in a single center in Wuhan,China[J].J Med Virol,2020,92(11): 2742-2750. doi: 10.1002/jmv.26174
[20] HUERTAS A,MONTANI D,SAVALE L,et al.Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)?[J].Eur Respir J,2020,56(1): 2001634. doi: 10.1183/13993003.01634-2020
[21] ACKERMANN M,VERLEDEN S E,KUEHNEL M,et al.Pulmonary vascular endothelialitis,thrombosis,and angiogenesis in covid-19[J].N Engl J Med,2020,383(2): 120-128. doi: 10.1056/NEJMoa2015432
[22] MERONI P L,ZAVAGLIA D,GIRMENIA C.Vaccinations in adults with rheumatoid arthritis in an era of new disease-modifying anti-rheumatic drugs[J].Clin Exp Rheumatol,2018,36(2): 317-328. http://d.wanfangdata.com.cn/periodical/ChlQZXJpb2RpY2FsRW5nTmV3UzIwMjEwMzAyEiBjZDE1NTcyOThiZTQ4MGUyN2NkYTcwYjdkYzI3ZTQ4MxoIbHhqOTN2amk%3D
[23] AKIYAMA S,HAMDEH S,MICIC D,et al.Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis[J].Ann Rheum Dis,2020,[Epub ahead of print].
[24] JUNG Y,KWON M,CHOI H G.Association between previous rheumatoid arthritis and COVID-19 and its severity: a nationwide cohort study in South Korea[J].BMJ Open,2021,11(10): e054753. doi: 10.1136/bmjopen-2021-054753
[25] QUARTUCCIO L,VALENT F,PASUT E,et al.Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: a population-based study in the first two months of COVID-19 outbreak in Italy[J].Joint Bone Spine,2020,87(5): 439-443. doi: 10.1016/j.jbspin.2020.05.003
[26] FITZGERALD G A.Misguided drug advice for COVID-19[J].Science,2020,367(6485): 1434. http://www.researchgate.net/publication/340074598_Misguided_drug_advice_for_COVID-19
[27] GIANFRANCESCO M,HYRICH K L,AL-ADELY S,et al.Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry[J].Ann Rheum Dis,2020,79(7): 859-866. doi: 10.1136/annrheumdis-2020-217871
[28] MIKULS T R,JOHNSON S R,FRAENKEL L,et al.American college of rheumatology guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: version 3[J].Arthritis Rheumatol,2021,73(2): e1-e12. doi: 10.1002/art.41889
[29] FANG L,KARAKIULAKIS G,ROTH M.Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection[J].Lancet Respir Med,2020,8(4): e21. doi: 10.1016/S2213-2600(20)30116-8
[30] LITTLE P.Non-steroidal anti-inflammatory drugs and covid-19[J].BMJ,2020,368: m1185. http://www.sciencedirect.com/science/article/pii/S0040595720300925
[31] RECOVERY COLLABORATIVE GROUP,HORBY P,LIM W S,et al.Dexamethasone in hospitalized patients with covid-19[J].N Engl J Med,2021,384(8): 693-704. doi: 10.1056/NEJMoa2021436
[32] ROCHWERG B,AGARWAL A,SIEMIENIUK R A,et al.A living WHO guideline on drugs for covid-19[J].BMJ Clin Res Ed,2020,370: m3379. http://www.bmj.com/content/370/bmj.m3379.short
[33] FAVALLI E G,BUGATTI S,KLERSY C,et al.Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis[J].Arthritis Res Ther,2020,22(1): 290. doi: 10.1186/s13075-020-02395-6
[34] SIEMIENIUK R A,BARTOSZKO J J,GE L,et al.Drug treatments for covid-19: living systematic review and network meta-analysis[J].BMJ,2020,370: m2980. http://www.bmj.com/content/370/bmj.m2980
[35] FROHMAN E M,VILLEMARETTE-PITTMAN N R,CRUZ R A,et al.Part Ⅱ.High-dose methotrexate with leucovorin rescue for severe COVID-19: An immune stabilization strategy for SARS-CoV-2 induced 'PANIC' attack[J].J Neurol Sci,2020,415: 116935. doi: 10.1016/j.jns.2020.116935
[36] HU K,WANG M,ZHAO Y,et al.A small-scale medication of leflunomide as a treatment of COVID-19 in an open-label blank-controlled clinical trial[J].Virol Sin,2020,35(6): 725-733. doi: 10.1007/s12250-020-00258-7
[37] KIM J W,KWAK S G,LEE H,et al.Baseline use of hydroxychloroquine or immunosuppressive drugs and the risk of coronavirus disease 2019[J].Korean J Intern Med,2021,[Epub ahead of print].
[38] FREDI M,CAVAZZANA I,MOSCHETTI L,et al.COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case-control study[J].Lancet Rheumatol,2020,2(9): e549-e556. doi: 10.1016/S2665-9913(20)30169-7
[39] VEIGA V C,PRATS J A G G,FARIAS D L C,et al.Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial[J].BMJ,2021,372: n84. http://www.bmj.com/content/372/bmj.n84.abstract
[40] FELDMANN M,MAINI R N,WOODY J N,et al.Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed[J].Lancet,2020,395(10234): 1407-1409. doi: 10.1016/S0140-6736(20)30858-8
[41] BACHILLER-CORRAL J,BOTEANU A,GARCIA-VILLANUEVA M J,et al.Risk of severe COVID-19 infection in patients with inflammatory rheumatic diseases[J].J Rheumatol,2021,48(7): 1098-1102. doi: 10.3899/jrheum.200755
[42] 徐东,曾小峰.阿巴西普治疗类风湿关节炎的机制及临床研究进展[J].中华风湿病学杂志,2020,24(10): 702-709. doi: 10.3760/cma.j.c141217-20200427-00177 [43] CANTINI F,NICCOLI L,MATARRESE D,et al.Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact[J].J Infect,2020,81(2): 318-356. http://www.sciencedirect.com/science/article/pii/S0163445320302280
[44] CAO Y,WEI J,ZOU L,et al.Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter,single-blind,randomized controlled trial[J].J Allergy Clin Immunol,2020,146(1): 137-146. doi: 10.1016/j.jaci.2020.05.019
[45] 曹雪涛.新型冠状病毒肺炎及新发传染病之免疫学研究[J].中华医学杂志,2021,101(1): 1-6. doi: 10.3760/cma.j.cn112137-20201211-03336 [46] WILLIAMSON E J,WALKER A J,BHASKARAN K,et al.Factors associated with COVID-19-related death using OpenSAFELY[J].Nature,2020,584(7821): 430-436. doi: 10.1038/s41586-020-2521-4
[47] CHENG C,LI C,ZHAO T,et al.COVID-19 with rheumatic diseases: a report of 5 cases[J].Clin Rheumatol,2020,39(7): 2025-2029. doi: 10.1007/s10067-020-05160-x
[48] SOY M,KESER G,ATAGVNDVZ P,et al.Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment[J].Clin Rheumatol,2020,39(7): 2085-2094. doi: 10.1007/s10067-020-05190-5
[49] WANG B,SHAO X,WANG D,et al.Vaccinations and risk of systemic lupus erythematosus and rheumatoid arthritis: a systematic review and meta-analysis[J].Autoimmun Rev,2017,16(7): 756-765. doi: 10.1016/j.autrev.2017.05.012
[50] FURER V,EVIATAR T,ZISMAN D,et al.Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study[J].Ann Rheum Dis,2021,80(10): 1330-1338. doi: 10.1136/annrheumdis-2021-220647
[51] BRAUN-MOSCOVICI Y,KAPLAN M,BRAUN M,et al.Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2[J].Ann Rheum Dis,2021,80(10): 1317-1321. doi: 10.1136/annrheumdis-2021-220503
计量
- 文章访问数: 1133
- HTML全文浏览量: 350
- PDF下载量: 63
下载:
苏公网安备 32100302010246号